AP
TXG icon

AlpInvest Partners’s 10x Genomics TXG Stock Holding History

AlpInvest Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,819
Closed -$285K – 24
2022
Q4 		$285K Sell
7,819
-2,552
-25% -$83.4K 0.08% 21
2022
Q3 		$295K Hold
10,371
– – 0.09% 23
2022
Q2 		$469K Buy
10,371
+3,991
+63% +$207K 0.16% 20
2022
Q1 		$485K Buy
6,380
+3,828
+150% +$335K 0.16% 23
2021
Q4 		$380K Buy
+2,552
New +$391K 0.14% 20
2021
Q2 		– Sell
-4,848
Closed -$877K – 24
2021
Q1 		$877K Buy
+4,848
New +$837K 0.44% 14
2020
Q4 		– Sell
-2,839
Closed -$354K – 12
2020
Q3 		$354K Buy
+2,839
New +$298K 0.57% 10

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

AlpInvest Partners's TXG Position: Q1 2023 in Review

AlpInvest Partners sold out of 10x Genomics (TXG) in Q1 2023, closing a stake of 7,819 shares — an estimated $285K sold.

AlpInvest Partners first reported a position in TXG in Q3 2020 and held it in 7 quarters. The position peaked at $877K in Q1 2021. 258 funds tracked by Wall St. Rank hold TXG as of Q1 2023.

  • AlpInvest Partners reported no remaining 10x Genomics position as of Q1 2023 after selling out during the quarter.
  • AlpInvest Partners sold 7,819 10x Genomics shares in Q1 2023, an estimated $285K.
  • AlpInvest Partners first reported a position in 10x Genomics in Q3 2020 and held it in 7 quarters.
  • AlpInvest Partners's 10x Genomics position peaked at $877K in Q1 2021.
  • 258 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2023.

Based on AlpInvest Partners's 13F filing for Q1 2023, filed 5 May 2023.